Convalescent plasma to treat COVID-19: Following the Argentinian lead.
作者信息
Tiberghien Pierre, Toussirot Eric, Richard Pascale, Morel Pascal, Garraud Olivier
机构信息
Etablissement Français du Sang, La Plaine St Denis, France; UMR RIGHT 1098 Inserm, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France.
UMR RIGHT 1098 Inserm, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France; CHU Besançon, Inserm CIC 1431, Besançon, France.
出版信息
Transfus Apher Sci. 2021 Jun;60(3):103161. doi: 10.1016/j.transci.2021.103161. Epub 2021 May 23.
Abstract
摘要
相似文献
1
Convalescent plasma to treat COVID-19: Following the Argentinian lead.用康复期血浆治疗新冠肺炎：效仿阿根廷的做法。
Transfus Apher Sci. 2021 Jun;60(3):103161. doi: 10.1016/j.transci.2021.103161. Epub 2021 May 23.
2
Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients.关于使用新冠康复者血浆治疗免疫功能低下患者的建议。
Semin Thromb Hemost. 2024 Jun;50(4):648-653. doi: 10.1055/s-0043-1776876. Epub 2023 Nov 20.
3
COVID-19: Herd immunity and convalescent plasma transfer therapy.新型冠状病毒肺炎：群体免疫与恢复期血浆输注疗法
J Med Virol. 2020 Sep;92(9):1380-1382. doi: 10.1002/jmv.25870. Epub 2020 Jul 11.
4
Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.关于新冠康复患者捐献的恢复期血浆（CBP）的评论
Transfus Apher Sci. 2021 Jun;60(3):103108. doi: 10.1016/j.transci.2021.103108. Epub 2021 Mar 2.
5
A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report.1例新型冠状病毒肺炎伴细胞因子风暴患者，先后连续采用治疗性血浆置换和恢复期血浆输注治疗：病例报告
J Med Virol. 2021 Apr;93(4):1854-1856. doi: 10.1002/jmv.26630. Epub 2020 Nov 10.
6
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.恢复期血浆治疗 COVID-19：美国国立卫生研究院 COVID-19 治疗指南专家组的观点。
Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25.
7
First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.新冠病毒相关严重再生障碍性贫血患儿接受恢复期血浆输注的首例病例。
Transfus Apher Sci. 2020 Oct;59(5):102866. doi: 10.1016/j.transci.2020.102866. Epub 2020 Jul 1.
8
Convalescent plasma to treat COVID-19: clinical experience and efficacy.恢复期血浆治疗 COVID-19：临床经验和疗效。
Aging (Albany NY). 2021 Mar 18;13(6):7758-7766. doi: 10.18632/aging.202795.
9
COVID-19 convalescent plasma: Interim recommendations from the AABB.新型冠状病毒肺炎康复者血浆：美国血库协会临时建议
Transfusion. 2021 Apr;61(4):1313-1323. doi: 10.1111/trf.16328. Epub 2021 Mar 7.
10
Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report.新型冠状病毒肺炎康复者血浆可提高重症监护病房生存率。初步报告。
Transfus Apher Sci. 2020 Oct;59(5):102848. doi: 10.1016/j.transci.2020.102848. Epub 2020 Jun 10.
引用本文的文献
1
Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.康复期新冠病毒肺炎血浆治疗：回归基础与伦理，以及后续步骤
Transfus Clin Biol. 2021 Aug;28(3):225-227. doi: 10.1016/j.tracli.2021.07.005.
本文引用的文献
1
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.COVID-19 患者住院期间的恢复期血浆治疗（RECOVERY）：一项随机对照、开放标签、平台试验。
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
2
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
3
Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021.2020年3月1日至2021年1月2日美国因新冠病毒病及其他原因导致的超额死亡人数
JAMA. 2021 Apr 2;325(17):1786-9. doi: 10.1001/jama.2021.5199.
4
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.mRNA疫苗接种可增强由SARS-CoV-2感染引发的交叉变异中和抗体。
Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175.
5
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.从恢复期血浆中生产抗 SARS-CoV-2 超免疫球蛋白。
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
6
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
7
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.恢复期血浆治疗与 COVID-19 患者临床结局的关联：系统评价和荟萃分析。
JAMA. 2021 Mar 23;325(12):1185-1195. doi: 10.1001/jama.2021.2747.
8
South American Hemorrhagic Fevers: A summary for clinicians.南美洲出血热：临床医生须知。
Int J Infect Dis. 2021 Apr;105:505-515. doi: 10.1016/j.ijid.2021.02.046. Epub 2021 Feb 18.
9
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.IgM 在恢复期血浆对 SARS-CoV-2 的中和活性中起主要作用。
Cell Rep. 2021 Mar 2;34(9):108790. doi: 10.1016/j.celrep.2021.108790. Epub 2021 Feb 10.
10
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
Zotero 插件